Supernus Pharmaceuticals SUPN License — Contract Liabilities
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Supernus Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerLiability.
The official record: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Supernus Pharmaceuticals's license — contract liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Supernus Pharmaceuticals's license — contract liabilities?
- Supernus Pharmaceuticals (SUPN) reported license — contract liabilities of $90M in Q1 2026.
- What does license — contract liabilities mean?
- This metric represents the company's obligation to transfer goods or services to a customer for which the company has already received consideration or for which an amount of consideration is due. In the context of licensing, it typically reflects deferred revenue from upfront payments or non-refundable fees that have not yet met the criteria for revenue recognition. Monitoring this balance provides insight into future revenue potential and the timing of performance obligation fulfillment.